Association of IL-1 beta and IL-6 Gene Expression and some Biochemical Indicators with Polycystic Ovary Syndrome in Iraqi Women
DOI:
https://doi.org/10.22317/jcms.v12i1.2114Keywords:
Gene Expression, Interleukin-1beta, Interleukin-6, Interleukins, Polycystic Ovary SyndromeAbstract
Objectives: This study aimed to analyze hormone levels (FSH, LH, progesterone, prolactin, free testosterone, TSH), HbA1c, HDL, LDL, and gene expression of interleukin-1β and interleukin-6 and examine their relationship with PCOS.
Methods: The study included 100 women, 60 with polycystic ovarian syndrome (diagnosed) and 40 age matched, healthy women (controls). It was investigated hormones (FSH, LH, progesterone, prolactin, free testosterone, TSH), HbA1c, HDL, and LDL in blood. IL-1β and IL-6 genes’ relative expression levels were measured by quantitative Real Time reverse transcription-Polymerase Chain Reaction (RT-qPCR).
Results: The level of FSH, LH, prolactin, free testosterone, TSH, HbA1c and LDL were significantly higher in women with polycystic ovarian syndrome than in normally women (mean:9.41 ± 3.39 vs. 4.77 ± 1.31 IU/L, 25.51 ± 6.98 vs. 4.25 ± 2.62 IU/L, 15.36 ± 11.15 vs. 10.30 ± 7.75 ng/mL, 2.41 ± 0.97 vs. 0.91 ± 0.50 ng/dL, 3.00 ± 1.62 vs. 2.38 ± 0.99 mIU/L, 5.31 ± 0.94 vs. 4.7 ± 0.68% and 2.95 ± 0.86 vs. 2.62 ± 0.69 mmol/L, respectively); in contrast, progesterone and HDL concentrations were non significantly in the patients with PCOS than in the normally women (mean: 0.96 ± 0.69 vs. 0.83 ± 0.35 ng/mL, 1.12 ± 0.42 vs. 1.50 ± 0.21 mmol/L, respectively). The findings demonstrated that both the interleukin-1β and interleukin-6 genes in the polycystic ovarian syndrome and control groups had higher fold frequencies, with fold heights greater than 1.
Conclusion: The findings show different hormonal and metabolic change in the patient population, along with increased inflammatory activity, which suggests that the illness process involves a combination of inflammatory and endocrine pathways. IL-1β and free testosterone demonstrated promising diagnostic performance and may represent potential biomarkers pending further validation in larger studies.
References
Teede, H. J., et al., Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil. Steril. 2023.
Yadav, S., et al., Direct economic burden of mental health disorders associated with Polycystic ovary syndrome: systematic review and meta-analysis. eLife. 2023. 12: e85338.
Lauritsen, M. P., Svendsen, P. F., Andersen, A. N., Diagnostic criteria for polycystic ovary syndrome. Ugeskr Laeger. 2024. 181: 61–74.
Escobar-Morreale, H. F., Defining P.C.O.S.: A syndrome with an intrinsic heterogeneous nature. Polycystic Ovary Syndr. 2022. 3–13.
Escobar-Morreale, H. F., Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 2018. 145.
Khorkova, O., Stahl, J., Joji, Volmar, A. C., Wahlestedt, H. C., Amplifying gene expression with RNA-targeted therapeutics. Nat. Rev. Drug Discov. 2023. 227: 539–561.
De Vane, G. W., Czekala, N. M., Judd, H. L., Yen, S. S., Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am. J. Obs. Obstet. Gynecol. 1975. 121: 496–500.
Di Lorenzo, M., Cacciapuoti, N., Lonardo, M. S., Nasti, G., Gautiero, C., Belfiore, A., Guida, B., Chiurazzi, M., Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review. Curr. Nutr. Rep. 2023. 3: 527–544.
Ding, H., Zhang, J., Zhang, F., Zhang, S., Chen, X., Liang, W., Xie, Q., Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Front. Endocrinol. 2021. 12: 1764.
Wawrzkiewicz-Jałowiecka, A., Kowalczyk, K., Trybek, P., Jarosz, T., Radosz, P., Setlak, M., Madej, P., In Search of New Therapeutics—Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. Int. J. Mol. Sci. 2020. 21: 7054.
Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., Abdollahi, M., Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int. J. Mol. Sci. 2022. 23: 583.
Rashid, N., Nigam, A., Saxena, P., Jain, S. K., Wajid, S., Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome. Inflammation Research. 2017. 66(7): 621–636.
dos Santos, T. B., de Paula, H. K., Balarin, M. A. S., et al., Can the genetic polymorphisms of the folate metabolism have an influence in the polycystic ovary syndrome? Archives of Endocrinology and Metabolism. 2019.
Alkhuriji, A. F., Al Omar, S. Y., Babay, Z. A., El-Khadragy, M. F., Mansour, L. A., Alharbi, W. G., Khalil, M. I., Association of IL-1β, IL-6, TNF-α, and TGFβ1 Gene Polymorphisms with Recurrent Spontaneous Abortion in Polycystic Ovary Syndrome. Dis Markers. 2020. 6076274.
Popovic, M., Sartorius, G., Christ-Crain, M., Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1? Semin Immunopathol. 2019. 41: 447–459.
González, F., Nutrient-induced inflammation in polycystic ovary syndrome: role in the development of metabolic aberration and ovarian dysfunction. Semin Reprod Med. 2015. 33: 276–286.
González, F., Mather, K. J., Considine, R. V., Abdelhadi, O. A., Acton, A. J., Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2020. 319: 744–752.
Taieb, A., Feryel, A., Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State-of-the-Art Review. Diagnostics. 2024. 14(22): 2578.
Carmina, E., Dreno, B., Lucky, W. A., Agak, W. G., Dokras, A., Kim, J. J., Lobo, R. A., Ramezani Tehrani, F., Dumesic, D., Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Endocr Soc. 2022. 6(3).
Amuzescu, A., Tampa, M., Matei, C., Georgescu, S. R., Adult Female Acne: Recent Advances in Pathophysiology and Therapeutic Approaches. Cosmetics. 2024. 11: 74.
Sánchez-Pellicer, P., Navarro-Moratalla, L., Núñez-Delegido, E., Agüera-Santos, J., Navarro-López, V., How Our Microbiome Influences the Pathogenesis of Alopecia Areata. Genes. 2022. 14;13(10): 1860.
Sadgrove, N., Batra, S., Barreto, D., Rapaport, J., An Updated Etiology of Hair Loss and the New Cosmeceutical Paradigm in Therapy: Clearing ‘the Big Eight Strikes’. Cosmetics. 2023. 10.
Ahmad, H. Y., Rather, H. A., Kumar, N. R., Basheer, M., Reshi, M. S., A review on critical appraisal and pathogenesis of polycystic ovarian syndrome. Endocrine and Metabolic Science. 2024. 14: 100162.
Taieb, A., Feryel, A., Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State-of-the-Art Review. Diagnostics. 2024. 14: 2578.
Szybiak-Skora, W., Cyna, W., Lacka, K., New Insights in the Diagnostic Potential of Sex Hormone-Binding Globulin (SHBG)—Clinical Approach. Biomedicines. 2025. 13: 1207.
Unluhizarci, K., Hacioglu, A., Taheri, S., Karaca, Z., Kelestimur, F., Idiopathic hirsutism: Is it really idiopathic or is it misnomer? World J Clin Cases. 2023. 16;11(2): 292–298.
Singh, S., Kulshrestha, R., Verma, J., Nigam, V., Kulshrestha, M., Uncovering ovarian reserve: Insights into hormones, lipids, and essential metals. Indian J Obstet Gynecol Res. 2024. 226–231.
Mastnak, L., Herman, R., Ferjan, S., Janež, A., Jensterle, M., Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects. Life. 2023. 13: 2124.
Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Livadas, S., Thymis, J., Peppa, M., Kalantaridou, S., Oikonomou, E., et al., The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment. Medicina. 2024. 60: 1656.
Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., Samie, R., The last update on polycystic ovary syndrome (PCOS), diagnosis criteria, and novel treatment. Endocrine and Metabolic Science. 2025. 17: 100228.
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., Kumar, M., Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. J Clin Med. 2023. 11;12(4): 1454.32.
Thapa, S., Bhusal, K., Hyperprolactinemia. StatPearls [Internet]. 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537331/.
Szukiewicz, D., Current Insights in Prolactin Signaling and Ovulatory Function. Int. J. Mol. Sci. 2024. 25: 1976.
Richard, A. J., White, U., Elks, C. M., et al., Adipose Tissue: Physiology to Metabolic Dysfunction. Endotext [Internet]. 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555602/.
Baldelli, S., Aiello, G., Mansilla Di Martino, E., Campaci, D., Muthanna, F. M. S., Lombardo, M., The Role of Adipose Tissue and Nutrition in the Regulation of Adiponectin. Nutrients. 2024. 16: 2436.
Khmil, M., Khmil, S., Marushchak, M., Hormone Imbalance in Women with Infertility Caused by Polycystic Ovary Syndrome: Is There a Connection with Body Mass Index? Open Access Maced J Med Sci. 2020. 8: 731–737.
Crawford, M., Kennedy, L., Testosterone replacement therapy: role of pituitary and thyroid in diagnosis and treatment. Transl Androl Urol. 2016. 5(6): 850–858.
Eser, B., Islimye Taskin, M., Hismiogullari, A. A., Aksit, H., Bodur, A. S., The effects of IL-1A and IL-6 genes polymorphisms on gene expressions, hormonal and biochemical parameters in polycystic ovary syndrome. J Obstet Gynaecol. 2017. 37(3): 358–362.
Zhai, Y., Pang, Y., Systemic and ovarian inflammation in women with polycystic ovary syndrome. J Reprod Immunol. 2022. 151: 103628.
Guo, R., Zheng, Y., Yang, J., Zheng, N., Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015. 16(1): 5.
Mazloomi, S., Barartabar, Z., Pilehvari, S., The Association Between Increment of Interleukin-1 and Interleukin-6 in Women with Polycystic Ovary Syndrome and Body Mass Index. J Reprod Infertil. 2023. 24(1): 26–34.
Guo, R., Zheng, Y., Yang, J., Zheng, N., Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015. 16(1): 5.
Wu, H., Yu, K., Yang, Z., Associations between TNF-α and interleukin gene polymorphisms with polycystic ovary syndrome risk: a systematic review and meta-analysis. J Assist Reprod Genet. 2015. 32(4): 625–634.
Alkhuriji, A. F., Al Omar, S. Y., Babay, Z. A., El-Khadragy, M. F., Mansour, L., Alharbi, W. G., Khalil, M. I., Association of IL-1β, IL-6, TNF-α, and TGFβ1 Gene Polymorphisms with Recurrent Spontaneous Abortion in Polycystic Ovary Syndrome. Dis Markers. 2020. 5: 6076274.
Taylor, M. K., Inflammatory Gene Expression in Women Diagnosed with Polycystic Ovarian Syndrome. Electronic Theses & Dissertations. 2016. 224.
Rostamtabar, M., Esmaeilzadeh, S., Tourani, M., Rahmani, A., Baee, M., Shirafkan, F., et al., Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome. J Cell Physiol. 2021. 236(2): 824–838.
Mazloomi, S., Barartabar, Z., Pilehvari, S., The Association Between Increment of Interleukin-1 and Interleukin-6 in Women with Polycystic Ovary Syndrome and Body Mass Index. J Reprod Infertil. 2023. 24(1): 26–34.
Borthakur, A. D., Prabhu, Y. Valsala Gopalakrishnan, A., Role of IL-6 signalling in Polycystic Ovarian Syndrome associated inflammation. J Reprod Immunol. 2020. 141: 103155.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
